To the Editor An increasing body of data has shown that East Asian patients have a lower risk of thrombosis and an increased risk of bleeding during antithrombotic treatment for acute coronary syndrome than do white patients.1 The Bivalirudin in Acute Myocardial Infarction vs Heparin and GPI Plus Heparin Trial (BRIGHT) was conducted in China.2 Most of the patients received a loading dose of clopidogrel of 300 mg to 600 mg.
Young-Hoon Jeong, Diana A. Gorog, Jeong Su Kim. Varying Responses to Antithrombotic Treatment by Race/Ethnicity. JAMA. 2015;314(6):624–625. doi:10.1001/jama.2015.7381